Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is the standard of care for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusions (RVO). This evidence concerns the gene VEGFA and wet macular degeneration.